Tore K Kvien Selected Research

Antirheumatic Agents (DMARD)

1/2022	Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study.
1/2022	Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
11/2021	Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis.
10/2021	Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis.
1/2021	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
1/2020	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
1/2020	Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
1/2020	Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.
1/2020	Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
1/2020	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tore K Kvien Research Topics

Disease

113	Rheumatoid Arthritis 10/2022 - 07/2003
29	Psoriatic Arthritis 06/2022 - 03/2007
20	Inflammation (Inflammations) 01/2022 - 07/2003
19	Pain (Aches) 01/2022 - 01/2002
19	Ankylosing Spondylitis 01/2022 - 02/2005
17	Rheumatic Diseases (Rheumatism) 01/2018 - 08/2007
16	Necrosis 10/2022 - 06/2010
14	Arthritis (Polyarthritis) 09/2021 - 10/2007
13	Fatigue 01/2022 - 02/2005
13	Joint Diseases (Joint Disease) 01/2020 - 03/2007
10	Axial Spondyloarthritis 06/2022 - 01/2014
9	Osteoarthritis 01/2022 - 09/2007
8	Synovitis 12/2017 - 01/2009
6	Infections 06/2022 - 06/2010
6	Cardiovascular Diseases (Cardiovascular Disease) 11/2018 - 02/2011
5	Crohn Disease (Crohn's Disease) 12/2021 - 10/2017
5	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2021 - 07/2016
5	Osteoporosis 01/2017 - 07/2002
5	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 04/2013 - 06/2007
4	Gout 01/2022 - 11/2020
4	Congenital Abnormalities (Deformity) 03/2007 - 06/2003
3	Ulcerative Colitis 12/2021 - 10/2017
3	Neoplasms (Cancer) 08/2021 - 06/2010
3	Arthralgia (Joint Pain) 03/2021 - 11/2017
2	Obesity 01/2022 - 08/2021
2	Chronic Disease (Chronic Diseases) 01/2022 - 01/2009
2	Osteophyte 11/2020 - 01/2013
2	Tenosynovitis 11/2017 - 03/2011
2	Atherosclerosis 01/2016 - 10/2015
2	Musculoskeletal Pain 02/2003 - 01/2002
1	Overweight 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 09/2021

Drug/Important Bio-Agent (IBA)

56	Antirheumatic Agents (DMARD)IBA 01/2022 - 01/2009
25	Biological ProductsIBA 01/2022 - 06/2010
17	Tumor Necrosis Factor InhibitorsIBA 10/2022 - 03/2007
17	C-Reactive ProteinIBA 01/2022 - 02/2005
14	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 02/2010
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2007
9	Rituximab (Mabthera)FDA Link 03/2022 - 06/2011
9	Pharmaceutical PreparationsIBA 01/2022 - 03/2007
8	Infliximab (Remicade)FDA Link 01/2022 - 08/2005
8	Proteins (Proteins, Gene)FDA Link 12/2017 - 08/2007
8	Anti-Citrullinated Protein AntibodiesIBA 11/2011 - 01/2009
7	Rheumatoid FactorIBA 09/2021 - 01/2010
7	tocilizumab (atlizumab)FDA Link 01/2020 - 04/2013
6	secukinumabIBA 06/2022 - 03/2019
6	Adalimumab (Humira)FDA Link 06/2022 - 07/2010
6	AntibodiesIBA 01/2022 - 01/2009
6	Prostaglandins AIBA 01/2022 - 01/2017
5	GlucocorticoidsIBA 06/2022 - 02/2016
5	ametantrone (HAQ)IBA 03/2021 - 10/2007
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 08/2005
5	Biosimilar PharmaceuticalsIBA 01/2018 - 03/2013
5	Leukocyte L1 Antigen Complex (Calgranulin)IBA 12/2017 - 08/2007
5	LipidsIBA 10/2015 - 02/2011
5	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2015 - 06/2003
4	Uric Acid (Urate)IBA 01/2022 - 11/2020
4	Analgesics (Analgesic Drugs)IBA 11/2020 - 01/2002
4	Certolizumab Pegol FDA Link 01/2020 - 07/2012
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 02/2011
4	HLA-DRB1 Chains (HLA DRB1)IBA 04/2015 - 05/2010
4	AutoantibodiesIBA 04/2015 - 09/2011
4	4-hexyloxyaniline (HOA)IBA 01/2013 - 12/2010
3	cyclic citrullinated peptideIBA 01/2019 - 02/2009
3	Interleukin-6 (Interleukin 6)IBA 12/2017 - 04/2013
3	Etanercept (Enbrel)FDA Link 03/2014 - 08/2005
3	Immunoglobulin M (IgM)IBA 11/2011 - 01/2009
2	Abatacept (Orencia)FDA Link 10/2022 - 03/2014
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 04/2009
2	amsonic acid (DAS)IBA 01/2022 - 01/2020
2	omega-Chloroacetophenone (Mace)IBA 08/2021 - 01/2019
2	golimumab FDA Link 01/2020 - 03/2014
2	CholesterolIBA 01/2018 - 09/2012
2	CalciumIBA 01/2017 - 07/2002
2	Rosuvastatin Calcium (Crestor)FDA Link 01/2016 - 10/2015
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2015 - 02/2003
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 06/2014 - 02/2010
2	Peptides (Polypeptides)IBA 11/2013 - 01/2010
2	Indicators and Reagents (Reagents)IBA 07/2013 - 02/2005
2	LigandsIBA 04/2013 - 07/2003
2	Trinitrotoluene (TNT)IBA 09/2012 - 07/2012
2	AntigensIBA 05/2012 - 08/2011
2	EpitopesIBA 01/2012 - 08/2011
2	pro-brain natriuretic peptide (1-76)IBA 11/2010 - 01/2008
2	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedioneIBA 10/2007 - 01/2002
1	Janus Kinase InhibitorsIBA 10/2022
1	Interleukin-6 InhibitorsIBA 10/2022
1	COVID-19 VaccinesIBA 03/2022
1	Colchicine FDA LinkGeneric 01/2022
1	LeptinIBA 01/2022
1	Allopurinol (Remid)FDA LinkGeneric 01/2022
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 09/2021
1	ixekizumabIBA 03/2021
1	InterleukinsIBA 01/2020

Therapy/Procedure

27	Therapeutics 06/2022 - 08/2005
4	Biological Therapy 01/2022 - 09/2010
2	Injections 01/2020 - 01/2018
2	Drug Therapy (Chemotherapy) 08/2016 - 02/2003
2	Secondary Prevention 12/2013 - 02/2011
1	Pain Management 01/2022